Drug Trial Radar · NCT05649748
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
91
Actual
Start
Mar 7, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Treprostinil PalmitilDrug
Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
PlaceboDrug
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by SeverityTime frame: From screening up to last follow up visit (Up to approximately 26 months)
Locations
45 sites in 15 countries. Site status is shown where the registry gives one.
USA005
Jacksonville, Florida
USA011
Tampa, Florida
USA006
Chicago, Illinois
USA001
Chicago, Illinois
USA102
New York, New York
USA016
Dallas, Texas
ARG004
Córdoba, Argentina
ARG001
Córdoba, Argentina
ARG009
Quilmes, Buenos Aires, Argentina
ARG006
Rosario, Santa Fe Province, Argentina
ARG007
San Miguel de Tucumán, Tucumán Province, Argentina
AUT001
Vienna, Austria
AUT002
Linz, Upper Austria, Austria
BEL003
Brussels, Belgium
BRA004
Belo Horizonte, Minas Gerais, Brazil
BRA006
Porto Alegre, Rio Grande do Sul, Brazil
BRA002
Blumenau, Santa Catarina, Brazil
DNK001
Aarhus, Central Jutland, Denmark
GER005
Heidelberg, Baden-Wurttemberg, Germany
GER003
München, Bavaria, Germany
GER002
Lübeck, Schleswig-Holstein, Germany
ITA005
Monza, Italy
ITA001
Palermo, Italy
ITA004
Roma, Italy
ITA002
Pavia, Lombardy, Italy
JPN005
Sapporo, Hokkaido, Japan
JPN004
Sapporo, Hokkaido, Japan
JPN007
Kurume-shi, Hukuoka, Japan
JPN006
Tsukuba, Ibaraki, Japan
JPN002
Okayama, Okayama-ken, Japan
JPN003
Suita-Shi, Osaka, Japan
MYS005
Alor Star, Kedah, Malaysia
MYS002
Kuantan, Pahang, Malaysia
MYS004
Sungai Buloh, Selangor, Malaysia
MEX003
Mexico City, Mexico
MEX004
San Luis Potosí City, Mexico
MEX005
Lomas de Guevara, Jalisco, Mexico
MEX001
Monterrey, Nuevo León, Mexico
PHL002
Makati City, Philippines
PHL001
Quezon City, National Capital Region, Philippines
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.